Reviva Pharmaceuticals Announces First Patients Dosed in Pivotal Phase III Study and Long-Term Safety Trial Evaluating Brilaroxazine for the Treatment of Schizophrenia

Reviva Pharmaceuticals Holdings, Inc. announced that the first patients have been dosed in a pivotal Phase III study and long-term safety trial to assess Reviva’s new chemical entity brilaroxazine for the treatment of subjects with an acute exacerbation of schizophrenia.